home / stock / cprx / cprx news

CPRX News and Press, Catalyst Pharmaceuticals Inc. From 03/21/19

Stock Information
Company Name: Catalyst Pharmaceuticals Inc.
Stock Symbol: CPRX
Market: NASDAQ
Website: catalystpharma.com
Menu
CPRX CPRX Quote CPRX Short CPRX News CPRX Articles CPRX Message Board
Get CPRX Alerts

News, Short Squeeze, Breakout and More Instantly...
CPRX - Catalyst Pharmaceuticals (CPRX) To Present At Oppenheimer 29th Annual Healthcare Conference - Slideshow

The following slide deck was published by Catalyst Pharmaceuticals, Inc. in conjunction with this Read more ...

CPRX - Why 2019 U.S. Medical Device Market is Expected to Exceed Last Year Revenues

March 21, 2019 Palm Beach, FL – March 21, 2019 – A recent article in a medical device industry periodical, INN, said that: “2018 has been an important year for the medical device industry as M&A, technology and regulatory catalysts have impacted the market...

CPRX - Catalyst Pharmaceuticals, Inc. (CPRX) CEO Pat McEnany on Q4 2018 Results - Earnings Call Transcript

Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2018 Results Conference Call March 19, 2019 08:30 AM ET Company Participants Ali Grande - CFO Pat McEnany - Chairman and CEO Dr. Steve Miller - COO and Chief Scientific Officer Dan Brennan - Chief Commercial Officer Conference Call Pa...

CPRX - Catalyst Pharmaceuticals misses by $0.02

Catalyst Pharmaceuticals (NASDAQ: CPRX ): Q4 GAAP EPS of -$0.14 misses by $0.02 . More news on: Catalyst Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...

CPRX - Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

CORAL GABLES, Fla., March 18, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, tod...

CPRX - Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019

CORAL GABLES, Fla., March 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, tod...

CPRX - Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019

CORAL GABLES, Fla., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...
CPRX - Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome

CORAL GABLES, Fla., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, toda...

CPRX - Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders

CORAL GABLES, Fla., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic, neuromuscular and neurological diseases, tod...

CPRX - Net price of Catalyst Pharma's Firdapse to be $300K+ per year

Catalyst Pharmaceuticals ( CPRX +2.4% ) says that the net price per year for LEMS med Firdapse (amifampridine) will be $300K - 318,750 per year, representing about a 15 - 20% discount off the $375K list price. The net price includes rebates to insurers and other discounts. More news on...
Previous 10 Next 10